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One in six hospitalised people aged 65 or over will experience a new, significant adverse drug 
reaction (ADR) during their hospital stay. That is the major conclusion of a comprehensive systematic 
review and meta-analysis published in today’s Age & Ageing [1]. The high incidence is unlikely to 
surprise those who work in the acute care of older people, but arguably this figure only describes the 
tip of the iceberg. Any estimate of incidence relies crucially on outcome ascertainment, but most 
healthcare systems (and even scientific studies in this field) do not have a sensitive system to 
prospectively identify all events for adjudication as a potential ADR. Moreover, most validated 
systems of ADR ascertainment such as the Naranjo classification [2] or the WHO-UMC system [3] are 
fallible and none is universally accepted [4]. They lack sensitivity in identifying ADRs in people with 
multi-morbidity, mostly because they require exclusion of other potential causes before it can be 
ascertained that an ADR has ‘probably’ or ‘certainly’ occurred. For example, using these classification 
systems may make it falsely appear that people with Crohn’s disease are practically immune to all 
drug-related diarrhoea. Similarly, many drug-related symptoms would be classified as only ‘possible’ 
or even ‘unlikely’ ADRs in frail older people with multi-morbidity, even if they were real. ADR 
classification systems are based on the outdated ‘Ocham’s razor’ concept, that symptoms are best 
explained by a single condition or entity to form one correct, unifying diagnosis. In reality, 
geriatricians will be fully aware that most acute presentations in older people are multi-factorial, 
with medications frequently playing an important, but not easily quantifiable, part in their aetiology. 
Therefore, the true incidence of ADRs is likely to be much higher than the 16% reported in the meta-
analysis.                 
Further evidence for the likely under-reporting of ADRs in the published literature lies on closer 
inspection of the distribution of type of ADRs. Almost all electrolyte imbalances, one of the 
commonest of all ADRs, were allegedly due to potassium disorders. This is despite clear evidence 
that hyponatraemia is by far the commonest electrolyte disorder in hospitalised people and that 
older people are disproportionately affected [5]. This is likely to reflect the same limitations with 
outcome ascertainment, since hyponatraemia in older people is often multi-factorial [6] but 
medications play a key role [7].  Presumably, potassium imbalance is more likely to be considered 
directly linked to medications, but it seems implausible that they are genuinely 10 times more 
common than sodium disorders, as the new systematic review reports [1].      
These limitations are also likely to influence the findings on the drug and drug types that are most 
frequently linked to ADRs. Some, such as non-steroidal anti-inflammatory medications causing acute 
kidney injury or gastro-intestinal bleeding may be more likely to be picked up based on notoriety and 
because it is less likely that patients prescribed these drugs will have any other plausible explanation 
for their new symptoms. However, some medications, such as anti-depressants, may appear safer 
than they really are because almost their entire ADR profile could potentially be mis-attributed to 
the disease they are supposed to treat, or because they are considered risk factors rather than 
causes of adverse events, such as falls [8]. Although there is always a possibility of ‘confounding by 
indication’, this should not be used to dismiss concerns about drug safety and ADRs without 
objective evidence for such confounding.   
Unsurprisingly, given these limitations, the authors found enormous variations in estimates across 
studies beyond what might be expected from variations in case-mix and setting. The authors 
correctly point out the true burden of ADRs on older people in hospital is difficult to quantify. Some 
ADRs are arguably unavoidable when there is a strong indication for the drug and there is no 
evidence that a different dose, regime or agent would have resulted in a better risk/benefit ratio, 
and such factors are subjective and difficult to reliably ascertain. Research into avoidable ADRs rarely 
considered the impact on patient-reported measures such as quality of life, and even clinically 
important ADR-related outcomes such as length of stay were rarely reported [1]. Such deficiencies in 
the literature undermine the case for a more radical recalibration of prescribing decisions that is 
badly needed to stem the tide of polypharmacy and ADRs in older people. It is hard to argue that an 
internationally accepted ‘gold standard’ for ADR ascertainment would help more coherently and 
consistently define the extent of ADR-related morbidity and mortality, but such a standard should 
also work well in older people with multi-morbidity and polypharmacy, as the group most prone to 
ADRs.   
Beyond higher standards of pharmacovigilance and research to better define the extent of the 
problem, Jennings and colleagues recommend a greater focus on predicting and preventing ADRs. 
Lamentably, here again the evidence-base is found wanting. ADRs in frail older people are difficult to 
predict and none of the ADR-risk tools have sufficient predictive value for clinical use [9]. Perhaps 
this is unsurprising, as ADRs are a heterogeneous collection of symptoms and risk factors for 
individual ADRs vary widely. It may be difficult for a single scoring system to accurately 
simultaneously define the risk of any of diarrhoea or constipation or bleeding or any of the other 20 
diverse clinical presentations that together comprised 90% of all ADRs in the present systematic 
review [1]. Just four different drug classes – diuretics, antibiotics, anti-thrombotic agents and 
analgesics – accounted for over half of all ADRs. This may well represent an important opportunity 
for targeted interventions to reduce incident ADRs in hospital. However, as the authors 
acknowledge, their results are not entirely consistent with other systematic reviews that looked at 
ADRs in either other settings or in wider age groups or included ADRs that led to admission. Neither 
does this ‘black-list’ correlate particularly well with findings from studies employing other ways to 
define drug-related health burden, such as measuring the cumulative effects on physical function in 
community-dwelling older people[10], where anticholinergic and sedative medications seem most 
dangerous . Nevertheless, the findings of the current systematic review are helpful in focussing on 
new ADRs occurring in older people in hospital and revealing the high incidence of this problem, 
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